Loading clinical trials...
Loading clinical trials...
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the ins...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT07206225 · Non-muscle Invasive Bladder Cancer
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104)
Los Angeles, California
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102)
Orlando, Florida
University of Chicago Medical Center ( Site 0109)
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions